MoonLake Immunotherapeutics Class A MLTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $52.00
- Day Range
- $50.00–55.91
- 52-Week Range
- $35.11–64.98
- Bid/Ask
- $51.86 / $55.50
- Market Cap
- $3.48 Bil
- Volume/Avg
- 2.7 Mil / 352,233
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
MoonLake Immunotherapeutics is a clinical-stage biotechnology company engaged in leveraging Nanobody technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 50
- Website
- https://www.moonlaketx.com
Comparables
Valuation
|
Metric
|
MLTX
|
ADCT
|
NOVN
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 15.64 |
Price/Book Value | 6.68 | — | 5.27 |
Price/Sales | — | 4.22 | 4.65 |
Price/Cash Flow | — | — | 14.25 |
Price/Earnings
MLTX
ADCT
NOVN
Financial Strength
|
Metric
|
MLTX
|
ADCT
|
NOVN
|
|---|---|---|---|
Quick Ratio | 42.46 | 5.60 | 0.61 |
Current Ratio | 43.71 | 6.17 | 0.93 |
Interest Coverage | — | −2.85 | 12.34 |
Quick Ratio
MLTX
ADCT
NOVN
Profitability
|
Metric
|
MLTX
|
ADCT
|
NOVN
|
|---|---|---|---|
Return on Assets (Normalized) | −9.89% | −51.81% | 13.97% |
Return on Equity (Normalized) | −10.56% | — | 33.01% |
Return on Invested Capital (Normalized) | −10.07% | −1,069.85% | 20.66% |
Return on Assets
MLTX
ADCT
NOVN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Tdtycwwm | Cngg | $512.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Zssdfgs | Nvqfvb | $117.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Lyjwkyxwg | Nxztjcs | $111.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Ksgtqdnry | Qxmqpl | $34.4 Bil | |||
| argenx SE ADR
ARGX
| Xslqzcbg | Nbzx | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Fwmpjtl | Bczw | $29.2 Bil | |||
| Moderna Inc
MRNA
| Wfwqfpbwg | Dlbc | $23.1 Bil | |||
| United Therapeutics Corp
UTHR
| Qmszddpd | Zgnc | $15.8 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Lphgyrjw | Brqbk | $13.2 Bil | |||
| Incyte Corp
INCY
| Gdpgxvlt | Xcgbh | $13.0 Bil |
United States